The Relationship Between the Flow of Arteriovenous Fistula and Cardiac Function in Haemodialysis Patients

Sponsor

Sun Yat-sen University (Other)

Overall Status

Completed

CT.gov ID

NCT02747966

Collaborator

(none)

100

Enrollment

Location

Duration (Months)

2.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A prospective longitudinal surveillance for a period of 2 months. Sample - identify suitable Chronic Kidney Disease (CKD) patients who undergo HD with functioning AVF. Participants at various age range and both sexes are recruited to observe their access flow, access recirculation and cardiac function and assess their relationship.

Condition or Disease	Intervention/Treatment	Phase
Complication of Hemodialysis

Detailed Description

All patients recruited who met the inclusion criteria were investigated access flow, access recirculation and cardiac function(including cardiac output,cardiac index,central blood volume,et al).Measurement time is the beginning of HD session (first 30min to 1 hr),Middle of HD session (optional),and the end of the HD session (1hr to 30 min prior to end of session). The follow-up duration is 6 months and 12 months.Repeat the assessment at the above time points.

Study Design

Study Type:

Observational

Actual Enrollment :

100 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

Study of Access Flow ,Access Recirculation of Arteriovenous Fistula and the Relationship With Cardiac Function

Study Start Date :

Apr 1, 2009

Actual Primary Completion Date :

Apr 1, 2012

Actual Study Completion Date :

Apr 1, 2012

Outcome Measures

Primary Outcome Measures

to access the chang of the fistula blood flow in HD patients using Ultrasound Dilution method [Change of the fistula blood flow from baseline to 6 months]

Secondary Outcome Measures

Changes of the Cardiac Index (CI) during the course of hemodialysis therapy [from baseline to 6 months]
Changes of the Oxygen delivery ( Adequacy of hemoglobin level to Epoetin) during the course of hemodialysis therapy [from baseline to 6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients undergo HD with native AVF
AF of AVF between 300ml/min and 1800ml/min

Exclusion Criteria:

Patients whose AVF developed Access Recirculation (AR) which cannot be resolved at the time of measurement
Patients developed access or systemic infection during the study period